UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

Tomorrow is National Intern Day 2021! We are pleased to continue our mission of investing in the next generation of the workforce by welcoming 32 student interns to our second virtual internship program.

With more than 90 years of innovation, at UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Learn more about who we are at UCB.

This month in honor of Myasthenia Gravis (MG) Awareness Month, we have an opportunity to elevate the voices and needs of people with MG who remind us each day that our collective efforts can directly impact the everyday lives of MG patients – especially during times when immunocompromised individuals can face even more challenges than usual.

Our recent launch of dynamic targeting in the U.S. is providing UCB a better grasp of physician needs, which can lead to better healthcare outcomes. This is a key building block in UCB’s digital transformation journey providing a proven blueprint and lessons learned to continue innovating now and in the future. This initiative was recognized as the Most Valuable Data and Insights Initiative at the Reuters Pharma Awards USA 2020. Read how UCB has improved efficiencies for our teams and helped evolve the field experience. The article was originally published by ZS.

Congratulations to Anita Moser, Head of U.S. Neurology Assets and Optimization, and Erica Puntel, U.S. Neurology and Global Digital Business Transformation Communications Lead, for their recognition as Healthcare Businesswomen's Association (HBA) Rising Stars for 2021.

UCB is proud to be one of 26 members launching the IP PACT and we invite you to learn more about the commitments we are making to ensure our approach to IP delivers value for society, patients, and UCB.